ReviewSeminars in immunology2025
Oncolytic virus-mediated immunomodulation in glioblastoma: Insights from clinical trials and challenges.
Review in Seminars in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Reprogramming the immune orchestra for glioblastoma: oncolytic viruses and the B-cell connection.Cellular & molecular immunology · 2026Article
- Oncolytic virus M1 reinvigorates CD8Cellular & molecular immunology · 2026Article
- Next-generation immunotherapy biologics for glioblastoma.Frontiers in immunology · 2026Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The pivotal involvement of the host immune system in cancer therapy has dramatically reshaped therapeutic paradigms, inaugurating the era of immunotherapy. Nonetheless, antigen-specific immunotherapies encounter substantial hurdles within the highly immunosuppressive microenvironment of glioblastoma (GBM), which thwarts antitumor T-cell immunity. Oncolytic viruses (OVs), a form of immunotherapy that inflames the GBM microenvironment, have been subject to clinical evaluation, yielding promising outcomes. Evidence increasingly indicates that OVs can modify the GBM microenvironment from an immunosuppressive to an immune active state, facilitating enhanced antitumor responses. Clinical trials demonstrate that oncolytic virotherapy is generally well-tolerated, generating data about its immune-activating effects. "Window of opportunity" trials provide insights into viral replication, pre-existing immunity, and delivery methods. However, constraints in post-treatment sampling may impede comprehensive analyses of the virotherapy-induced biological and immunological changes. This review discusses current advancements and persistent challenges in GBM trials involving OVs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.